Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics
Rainer M, Mucke HA, Kruger-Rainer C,
Kraxberger E, Haushofer M, Jellinger KA.
Memory-Clinic and Department of Psychiatry,
Donauspital, Sozialmedizinisches Zentrum Ost,
Vienna, Austria.
J Neural Transm. 2001;108(11):1327-33


In a cross-sectional study of outpatients diagnosed with dementia of the Alzheimer type who had been treated with a broad variety of drugs supposed to improve cognition or to delay cognitive decline, we have investigated the effects of abruptly discontinuing therapy on cognition. Termination of therapy with any cholinesterase inhibitor was associated with a cognitive decline during the following 6-7 weeks which was significantly more pronounced than that experienced by patients who had received nootropic drugs or calcium channel blockers (3.41 vs. 1.17 points on the ADAS-Cog scale; -1.14 vs. -0.06 points on the MMSE scale). This effect was not modified by gender, apolipoprotein E genotype, or the extent of ventricular enlargement on CT scans. Its magnitude was comparable to the cognitive response observed in published clinical trials when cholinesterase therapy commenced, and also with the data obtained during a 6-week placebo washout phase.
New brain cells
Alzheimer's Disease
The memory switch?
Dumb-drug euphoria
Cholinesterase inhibitors
Alzheimer's Disease: resources and hotlinks
Alzheimer's Disease and Vitamin E supplements
Cholinesterase inhibitors for Alzheimer's disease
Memory-enhancing Neotrofin in Alzheimer's disease

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family